ADORA2A and non-small cell lung carcinoma: In the NCT02403193 trial, the authors used the A2AR antagonist NIR-178 (PBF-509) alone or in combination with anti PD-1 antibodies for NSCLC patients with advanced cancer who had failed standard therapies, including checkpoint inhibitors and TKI therapies.